Charl van Zyl manages the global development and commercialization of innovative solutions that create value for people living with neurological disorders, such as epilepsy and neuro-degenerative conditions. He is also in charge of UCB's corporate activities in Europe and International Markets.
His strategic business thinking, his track record of delivering results and his experience around the world are key to accompany UCB on its growth path.
Charl holds a degree in Medical Biochemistry and Business Administration from the University of Cape Town, South Africa. Prior to his current role, Charl led UCB’s Patient Value Operations.
He is a member of UCB’s Executive Committee and has been a member of the Board of BIO (Biotechnology Innovation Organization).